Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2015

View Archived Issues

Researchers describe novel RNAi-based bone anabolic strategy

SNP in ARNT2 gene linked to Asperger's syndrome

REGENXBIO licenses vector delivery technologies for mucopolysaccharidosis gene therapies

Novel assay for DNA methylation predicts outcome in AML patients

Teijin Pharma develops bifunctional M3 antagonist and beta2-agonist compounds

Pierre Fabre and CNRS patent DNMT inhibitors

Scientists describe IMP3 expression and chromosome 12p abnormalities in PMTT

Novel RORgt modulators identified for inflammatory diseases

Heptares Therapeutics describes discovery of mGlu5 receptor negative allosteric modulator

The Scripps Research Institute receives NCI grant to target Hippo-YAP pathway

Hydra Biosciences and Boehringer Ingelheim collaborate on TRP inhibitors for renal diseases

Voyager Therapeutics completes financing to fund AAV gene therapy development

Neothetics initiates phase III trials of LIPO-202 for reduction of subcutaneous abdominal fat

Ichor and Janssen to develop DNA vaccines for chronic HBV infection

Berg and collaborators aim to discover first biomarker for pancreatic cancer

AEternaZentaris plans confirmatory phase III trial of Macrilen in GHD diagnosis

Sthamin1 as a biomarker to distinguish ESS and ULMS from LM

Midatech and Dana-Farber Cancer Institute to collaborate on glioblastoma nanomedicines

Merck & Co. discloses HIV integrase inhibitors

Toray reports new analgesics

The CHDI Foundation discloses KMO inhibitors

University of Cologne presents apoptosis-inducing compounds

MolMed exercises option right on San Raffaele Hospital's CAR-CD44v6 project

Phase IIb trial of Nefecon for primary IgA nephropathy meets primary endpoint

Bayer expands copanlisib program with three new trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...